TSHA · Taysha Gene Therapies
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $5.30
Note written ·
Price against the kill line
22.6% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $5.30, on record since 11 November 2026. The shares are down 34.0% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $5.30, the 200-day average of closes as of 13 November 2026, which would show the shares leading the S&P 500 again. FDA feedback accepting a filing on the single-arm six-month interim data would point the same way.
Research onlyNot in the portfolio.
The business · as of
Taysha develops gene therapies for rare neurological diseases; its lead program, TSHA-102, targets Rett syndrome. It has no product revenue (reported revenue was $0.0 million in the quarter to 30 September 2026) and funds itself through equity offerings.
What is changing, and what follows · as of
- What is changing now
- On 12 November 2026 Taysha reported third-quarter 2026 results and said the process performance qualification manufacturing campaign for TSHA-102 is complete, with the pivotal data timing unchanged.
- What follows for the company
- Net loss was $39 million in the quarter to 30 September 2026 and free cash flow was −$142 million over four quarters; cash of $423 million is guided to last into the second half of 2028.
- What follows for its customers, suppliers and competitors
- Neurogene (NGNE), the closest Rett competitor, finished dosing its 25-patient Embolden trial and guides topline to the second half of 2027, after Taysha's guided first-half 2027 interim.
What the price assumes · as of
At the 13 November 2026 close (filed inputs to 12 November 2026) the shares trade at 175.3 times sales and 3.7 times book value, for an enterprise value of $961 million; earnings multiples are not meaningful. That holds only if TSHA-102 is approved and a launch replaces today's zero revenue before the cash runs out.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 12 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 0.0
- Operating margin (%)
- −516.0
- Net cash, cash less debt ($M)
- 376
- Enterprise value to sales (×)
- 175.3
All filed numbers
What Taysha Gene Therapies reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 0.0 | — | — |
| first filed | 0.0 | −100.0 | — |
| first filed | 0.0 | −100.0 | — |
| first filed | 5.5 | +171.3 | −516.0 |
| first filed | 0.0 | −100.0 | — |
| first filed | 2.0 | +78.6 | −1347.1 |
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −156 | −39.1 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +14.9 |
| Operating cash flow ($M) | −141 |
| Capital spending ($M) | Not available |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 423 |
| Debt ($M) non-current long-term debt | 47.3 |
| Net cash, cash less debt ($M) | 376 |
| Deferred revenue ($M) at 30 September 2025, filed 4 November 2025; −53.5% on a year | 5.5 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 357 |
| Market value ($M) | 1,337 |
| Enterprise value, market value plus net debt ($M) | 961 |
| Enterprise value to sales (×) | 175.3 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 3.7 |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 15.7% of shares outstanding sold short, 11.6 days of average trading to cover, −6.8% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $6.7M |
Linked companies · as of
- Competitors:
- NGNE
The thesis
Taysha Gene Therapies' Rett syndrome gene therapy, TSHA-102, is rated more likely to lag the S&P 500 than lead it over the next three months. The case turns on pivotal six-month interim data and Food and Drug Administration (FDA) feedback on the filing route, both guided to the first half of 2027. The third-quarter report on 12 November 2026 left that timing unchanged.
The company said on 12 November 2026 that its process performance qualification (PPQ) manufacturing campaign for TSHA-102 is complete. Results met predefined specifications and comparability criteria, according to MarketBeat's summary of the call. PPQ is the validation run a biologics license application (BLA) requires, so the manufacturing risk is largely cleared.
The shares closed at $4.10 on 13 November 2026, down 34.0% over three months and 43.8% below the 52-week intraday high of $7.30 on 6 May 2026. The close is below the $6.00 price of the June 2026 offering. No new patient data came with the quarter, and the data that decides the call falls after the three-month window.
Bullish and bearish views on Taysha Gene Therapies, Inc.
The bull case on Taysha Gene Therapies, Inc. (TSHA), in brief: manufacturing step is done. The bear case: the FDA route is unresolved.
Bull case
- Manufacturing step is done. Taysha completed the BLA-enabling PPQ campaign for TSHA-102, with results meeting predefined specifications and comparability criteria (third-quarter call, 12 November 2026). Management said it does not foresee a supply constraint.
- Funding runs past the readout. Cash and short-term investments were $423 million and debt $47 million at 30 September 2026, a net cash position of $376 million (10-Q filed 12 November 2026). Management guided runway into the second half of 2028, beyond both guided clinical events.
- Filing could come sooner. Management said a filing built on the six-month interim analysis could accelerate submission by at least two quarters, subject to the data and FDA discussions (third-quarter call, 12 November 2026).
- Early efficacy cleared the agreed bar. REVEAL Part A showed a 100% milestone response at 12 months in 12 patients against an FDA-aligned 33% threshold (company release, 22 June 2026). No severe treatment-related serious adverse events or dose-limiting toxicities appeared across 33 treated patients as of the August 2026 cutoff.
Bear case
- The FDA route is unresolved. The pivotal trial is open-label and single-arm, and its primary endpoint is a novel scale, the Rett Syndrome Developmental Milestone Assessment. FDA feedback is guided to the first half of 2027, and the agency could still ask for controlled data.
- The data wait is months long. The last pivotal participant is expected to reach the six-month assessment around the end of 2026. Taysha will release the interim results together with the FDA's feedback (third-quarter call, 12 November 2026).
- Cash burn is heavy. Free cash flow was −$142 million over the four quarters to 30 September 2026, and the third-quarter net loss was $39.1 million against $32.7 million a year earlier (10-Q and results release, 12 November 2026). The diluted share count rose 14.9% in a year.
- The shares trade below the offering price. The June 2026 follow-on priced at $6.00 and raised $230 million gross. The 52-week closing low of $3.51 came on 14 October 2026.
- One manufacturing site. Commercial manufacturing depends on a single Catalent facility in Harmans, Maryland. A Type B meeting with the FDA on manufacturing and chemistry matters is guided to the fourth quarter of 2026.
- A competitor is dosed. Neurogene's registrational Embolden Rett trial (25 patients) completed dosing, with topline guided to the second half of 2027 (Neurogene second-quarter update, 10 August 2026).
Price setup
The shares closed at $4.28 on 11 November 2026, $4.21 on 12 November 2026 and $4.10 on 13 November 2026. The session of the third-quarter report moved the close down 1.6% from the prior day, and the next session fell a further 2.6%. The results confirmed existing guidance and did not lift the shares.
The 50-day average of closes is $4.49 and the 200-day average of closes sits above it, so the shorter average is below the longer one. The nearest floor in the closes is the 52-week closing low of $3.51 on 14 October 2026. Above the last close are the 50-day average, the $6.00 June offering price and the 52-week intraday high of $7.30.
Across US stocks trading at least $5 million a day, the standard deviation of 63-session returns was 27% in 2026, so a three-month outcome for a single clinical-stage stock spans a wide range in either direction.
SEC filings since the June offering show no insider transactions and no new share issuance in the filings reviewed. The two filings on 12 November 2026 are the Form 8-K on results and the Form 10-Q for the quarter ended 30 September 2026.
Catalysts ahead
- ~31 December 2026 (est.): Type B meeting with the FDA on manufacturing and chemistry matters for TSHA-102. Company guidance puts the meeting in the fourth quarter of 2026; its outcome shows whether the FDA accepts the manufacturing package behind a filing.
- ~31 December 2026 (est.): Final REVEAL pivotal participant reaches the six-month assessment. It closes the data set for the six-month interim analysis that drives the first-half 2027 readout.
- ~31 March 2027 (est.): Requested FDA meeting on the biologics license application pathway, guided to later in the first quarter of 2027. Minutes from the meeting decide whether a single-arm, interim-driven filing is accepted.
- ~30 June 2027 (est.): REVEAL pivotal six-month interim topline data and FDA feedback, guided to the first half of 2027. This event settles the case; the company will release the data together with the FDA's feedback.
What would change the view
A daily close above $5.30, the 200-day average of closes as of 13 November 2026, which would show the shares leading the S&P 500 again. FDA feedback accepting a filing on the single-arm six-month interim data would point the same way.
What it trades with
Taysha trades with small-cap gene therapy and rare-disease developers, which move on financing conditions and FDA sentiment toward single-arm, surrogate-endpoint filings. Neurogene (NGNE) is the closest direct comparison in Rett syndrome. Its registrational topline, guided to the second half of 2027, follows Taysha's guided first-half 2027 interim. Sector-wide equity issuance or FDA policy news on gene therapy can move the shares independent of Taysha's own results.
The evidence, claim by claim (7)
- Cash and short-term investments of $423 million and debt of $47 million at 30 September 2026; net cash $376 million; runway guided into the second half of 2028. Taysha 10-Q for the quarter to 30 September 2026 and third-quarter 2026 results release · as of
- Net loss of $39.1 million ($0.10 per share) in the third quarter of 2026 versus $32.7 million a year earlier; nine-month net loss $128.2 million. Taysha third-quarter 2026 results release · as of
- Free cash flow was −$142 million over the four quarters to 30 September 2026; reported revenue was $0.0 million in each of the last three quarters. Taysha 10-Q for the quarter to 30 September 2026 · as of
- BLA-enabling process performance qualification campaign for TSHA-102 completed, with results meeting predefined specifications and comparability criteria. Taysha third-quarter 2026 earnings call, via MarketBeat · as of
- REVEAL pivotal six-month interim data and FDA feedback are guided to the first half of 2027; an FDA meeting could occur later in the first quarter of 2027. Taysha third-quarter 2026 earnings call, via MarketBeat · as of
- REVEAL Part A showed a 100% milestone response at 12 months in 12 patients against an FDA-aligned 33% threshold; no severe treatment-related serious adverse events or dose-limiting toxicities across 33 treated patients as of the August 2026 cutoff. Taysha 22 June 2026 data release; second-quarter 2026 results release · as of
- Neurogene's 25-patient Embolden registrational Rett trial completed dosing; topline guided to the second half of 2027. Neurogene second-quarter 2026 corporate update · as of
Sources
- Taysha Gene Therapies Q3 Earnings Call Highlights · marketbeat.com ·
- Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update · ir.tayshagtx.com
- Taysha Gene Therapies Q3 2026 Earnings Call Transcript · benzinga.com
Related · shared themes
QURE
uniQure
uniQure's Huntington's gene therapy AMT-130 cleared the FDA filing stage with priority review and a 1 May 2027 decision date, yet the…
IRON
Disc Medicine
Disc Medicine's shares are modestly favoured to beat the S&P 500 over three months because bitopertin passed its Phase 3 APOLLO trial on 19…
ZVRA
Zevra Therapeutics
Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026…
KOD
Kodiak Sciences
Kodiak Sciences' shares look more likely to lag the S&P 500 after a 161.8% three-month run that prices in the DAYBREAK win while share…
See also · stocks to watch